PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors

Completed · Phase 1

Conditions studied: Refractory Solid Tumors

In brief

Two cohorts of patients will be enrolled: Cohort A will consist of patients who are current smokers, and Cohort B will consist of patients who are current nonsmokers. There will be 24 patients enrolled in each cohort. Nonsmokers are patients who have not consumed tobacco or nicotine-containing products for 1 year before the start of the study. Patients classified as current smokers must have smoked a minimum of 10 cigarettes per day for up to 1 year. Patients who have smoked 1-9 cigarettes per day for up to 1 year, or more than 10 cigarettes per day for less than 1 year will not be eligible for this study.

Key facts

Study ID
NCT00759928
Run by
SCRI Development Innovations, LLC
People needed
48
Starts
2008-10-01
Expected to finish
2014-06-01
Last updated by the study team
2014-07-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.